Lacrifill^® is intended for use in adult patients experiencing dry eye symptoms. It is a preservative-free, cross-linked hyaluronic acid canalicular gel for lacrimal occlusion. Each administration of Lacrifill^® is proven to provide sustained dry eye relief for up to 6 months.¹

While Lacrifill^® is generally well tolerated, the most commonly reported adverse event is epiphora (overflow of tears). For a complete list of contraindications and potential adverse events, please consult the Instructions for Use.¹

Lacrifill^® is a CE-marked and FDA-cleared medical device, supplied in a pre-filled syringe containing 0.6 ml of gel, enough to fully fill both inferior canaliculi of a single patient.¹ It can be administered by trained eyecare professionals in a standard practice setting.¹ Lacrifill^® has a 3-year shelf-life and should be stored at room temperature (5–25°C).

Lacrifill^® conforms to each patient’s unique canalicular anatomy, eliminating the need for sizing and providing a simple, one-size-fits-all solution. Lacrifill^® is designed to support both patient comfort and long-lasting efficacy.^1,2

Dry eye disease can compromise preoperative measurements and surgical planning, increasing the risk of refractive error.^3,4 While most patients with pre-existing dry eye are asymptomatic before surgery, 87% become symptomatic after it.⁵

Managing the ocular surface perioperatively can help maximise surgical outcomes and avoid unsatisfactory vision, worsening symptoms, and patient dissatisfaction.^6,7

The efficacy and safety of Lacrifill was evaluated over 6 months in a randomised, double-masked clinical trial.¹

From baseline to 6 months, Lacrifill^® improved:

• Tear quantity
• Symptoms of dry eye
• Ocular surface health
• Tear stability